期刊文献+

噻唑烷二酮类药物改善2型糖尿病患者血脂谱的作用及其意义 被引量:6

下载PDF
导出
摘要 目的探讨噻唑烷二酮类药物改善2型糖尿病血脂代谢紊乱的可能性。方法2型糖尿病并发血脂异常患者82例,分为4组,第1组18例为对照组,单用二甲双胍治疗;第2组23例,用二甲双胍加罗格列酮治疗;第3组19例,用二甲双胍加辛伐他汀治疗;第4组22例,用二甲双胍加罗格列酮联合辛伐他汀治疗。均治疗4周,观察治疗前后各组的血脂变化。结果与治疗前比较,第2组三酰甘油(TG)下降10.5%,总胆固醇(TC)下降11.2%,低密度脂蛋白胆固醇(LDL-C)下降15.8%,高密度脂蛋白胆固醇(HDL-C)上升7.8%;第3组TG下降30.0%,TC下降20.7%,LDL-C下降35.2%,HDL-C上升32.5%;第4组TG下降45.2%,TC下降32.1%,LDL-C下降37.5%,HDL-C上升25.8%。4组之间比较,第3组的降脂效果优于第1,2组(P<0.05),第4组的血脂调节效果优于其他3组(P<0.05)。结论噻唑烷二酮类药物可以改善2型糖尿病的血脂代谢异常,但不能取代他汀类药物用于降脂治疗。噻唑烷二酮类药物联合他汀类药物可能为治疗2型糖尿病血脂代谢紊乱的新方案。
出处 《医药导报》 CAS 2006年第9期879-881,共3页 Herald of Medicine
  • 相关文献

参考文献11

  • 1Parulkar A A,Pendergras M L,Granda-Ayala R,et al.Nonhypoglycemic effects of thiazolidinedines[J].Ann Intern Med,2001,134(1):61 -71.
  • 2Boden G,Homko C,Mozzoli M,et al.Thiazolidinediones upregulate fatty acid uptake and oxidation in adipose tissue of diabetic patients[J].Diabetes,2005,54(3):880-885.
  • 3Tack C J,Smits P,Demacker P N,et al.Troglitazone decreases the proportion of small,dense LDL and increases the resistance of LDL to oxidation in obese subjects[J].Diabetes Care,1998,21 (2):796 -799.
  • 4Teruel T,Hernandez R,Rial E,et al.Rosiglitazone up-regulates lipoprotein lipase,hormone-sensitive lipase and uncoupling protein-1,and down-regulates insulin-induced fatty acid synthase gene expression in brown adipocytes of Wistar rats[J].Diabetologia,2005,48 (11):2011-2017.
  • 5Coort S L,Coumans W A,Bonen A,et al.Divergent effects of rosiglitazone on protein-mediated fatty acid uptake in adipose and in muscle tissues of Zucker rats[J].J Lipid Res,2005,46 (6):1295 -1302.
  • 6Kim H,Haluzik M,Gavrilova O,et al.Thiazolidinediones improve insulin sensitivity in adipose tissue and reduce the hyperlipidaemia without affecting the hyperglycaemia in a transgenic model of type 2diabetes[J].Diabetologia,2004,47 (12):2215-2225.
  • 7Wilson-Fritch L,Nicoloro S,Chouinard M,et al.Mitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone[J].J Clin Invest,2004,114(9):1281-1289.
  • 8Wagner J A,Larson P J,Weiss S,et al.Individual and combined effects of peroxisome proliferator-activated receptor and {gamma}agonists,fenofibrate and rosiglitazone,on biomarkers of lipid and glucose metabolism in healthy nondiabetie volunteers[J].J Clin Pharmacol,2005,45 (5):504-513.
  • 9Van Wijk J P,de Koning E J,Castro C M,et al.Rosiglitazone improves postprandial triglyceride and free fatty acid metabolism in type 2 diabetes[J].Diabetes Care,2005,28 (4):844-849.
  • 10Tan G D,Fielding B A,Currie J M,et al.The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes[J].Diabetologia,2005,48 (1):83-95.

同被引文献49

引证文献6

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部